Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Takaho Okada

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112724055. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers

Papers 10

  1. Postoperative Carbohydrate Antigen 19-9 Level as a Good Indicator of Ineffective Response to the Currently Recommended S-1 Adjuvant Chemotherapy for Pancreatic… First author DOI 10.1245/s10434-023-14440-0↗
  2. ASO Author Reflections: Postoperative Carbohydrate Antigen 19-9 Levels Become a Reliable Biomarker for Establishing Intensity-Stratified Adjuvant Treatments in… First author DOI 10.1245/s10434-023-14506-z↗
  3. Pancreatic Ductal Adenocarcinoma Concomitant with Main Duct Type Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Case Report. Co-author DOI 10.12659/ajcr.932565↗
  4. [Detection of small pancreatic cancer during surveillance of the main pancreatic duct stenosis]. Co-author DOI 10.11405/nisshoshi.116.99↗
  5. Predictive Value of Localized Stenosis of the Main Pancreatic Duct for Early Detection of Pancreatic Cancer. Co-author DOI 10.5946/ce.2019.018↗
  6. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  7. [A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery]. Co-author PMID 25731467↗
  8. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutiona… Co-author DOI 10.1245/s10434-013-3129-9↗
  9. [A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer]. Co-author PMID 24393949↗
  10. Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer. Co-author DOI 10.1007/s12328-011-0257-2↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takashi Tsuchiya · 3 shared papers, 2021–2024 · strength 0.50
  2. Kyohei Ariake · 2 shared papers, 2024 · strength 0.39
  3. Kei Ito · 3 shared papers, 2019–2021 · strength 0.28
  4. Yoshihide Kanno · 3 shared papers, 2019–2021 · strength 0.28
  5. Toshitaka Sakai · 2 shared papers, 2019–2021 · strength 0.19
  6. Keisuke Yonamine · 2 shared papers, 2019–2021 · strength 0.19
  7. Kaori Masu · 2 shared papers, 2019 · strength 0.17
  8. Toji Murabayashi · 2 shared papers, 2019 · strength 0.17
  9. Michiaki Unno · 5 shared papers, 2011–2014 · strength 0.15
  10. Fuyuhiko Motoi · 5 shared papers, 2011–2014 · strength 0.15
  11. Yu Katayose · 4 shared papers, 2011–2014 · strength 0.12
  12. Shinichi Egawa · 4 shared papers, 2011–2014 · strength 0.12
  13. Kei Nakagawa · 3 shared papers, 2013–2014 · strength 0.09
  14. Yuki Fujii · 1 shared paper, 2019 · strength 0.08
  15. Hiroshi Yoshida · 2 shared papers, 2013–2014 · strength 0.06
  16. Masamichi Mizuma · 2 shared papers, 2013–2014 · strength 0.06
  17. Takanori Morikawa · 2 shared papers, 2013–2014 · strength 0.06
  18. Shinichi Yabuuchi · 1 shared paper, 2014 · strength 0.03
  19. Kei Kawaguchi · 1 shared paper, 2014 · strength 0.03
  20. Hajime Taniguchi · 1 shared paper, 2014 · strength 0.03
  21. Tomoo Kosuge · 1 shared paper, 2014 · strength 0.03
  22. Keita Wada · 1 shared paper, 2014 · strength 0.03
  23. Hiroyuki Shinchi · 1 shared paper, 2014 · strength 0.03
  24. Yoshiaki Murakami · 1 shared paper, 2014 · strength 0.03
  25. Sohei Satoi · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.